These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 26774923)

  • 21. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis, hypoglycaemic, hypolipidemic and PPARγ agonist activities of 5-(2-Alkyl/aryl-6-Arylimidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene-1,3-thiazolidinediones.
    Khazi MI; Belavagi NS; Kim KR; Gong YD; Khazi IA
    Chem Biol Drug Des; 2013 Aug; 82(2):147-55. PubMed ID: 23581650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma.
    Sauer S
    Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
    Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
    Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.
    Shukla S; Kumar P; Das N; Moorthy NS; Shrivastava SK; Trivedi P; Srivastava RS
    Med Chem; 2012 Sep; 8(5):834-45. PubMed ID: 22741802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
    Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
    Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P; Bhat ZR; Bhat S; Kumar R; Kumar R; Tikoo K; Gupta J; Khurana N; Kaur J; Khatik GL
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4(3H)-one derivatives as potential PPARγ and SUR agonists.
    Ibrahim MK; Eissa IH; Alesawy MS; Metwaly AM; Radwan MM; ElSohly MA
    Bioorg Med Chem; 2017 Sep; 25(17):4723-4744. PubMed ID: 28720328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
    Naim MJ; Alam MJ; Nawaz F; Naidu VGM; Aaghaz S; Sahu M; Siddiqui N; Alam O
    Bioorg Chem; 2017 Aug; 73():24-36. PubMed ID: 28582649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
    Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
    J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids.
    Mourad AAE; Mourad MAE
    Life Sci; 2020 Oct; 259():118270. PubMed ID: 32814067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of [[(heterocycloamino)alkoxy] benzyl]-2,4-thiazolidinediones as PPARgamma agonists.
    Jeon R; Kim YJ; Cheon Y; Ryu JH
    Arch Pharm Res; 2006 May; 29(5):394-9. PubMed ID: 16756084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thiazolidinedione derivatives as PTP1B inhibitors with antihyperglycemic and antiobesity effects.
    Bhattarai BR; Kafle B; Hwang JS; Khadka D; Lee SM; Kang JS; Ham SW; Han IO; Park H; Cho H
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6161-5. PubMed ID: 19783142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
    Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
    Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
    Wang M; Tafuri S
    J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.